Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen
- PMID: 8805677
Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen
Abstract
Protein tyrosine phosphatase-like IA-2 is a major autoantigen in insulin-dependent diabetes. It has been identified as both a specificity of cytoplasmic islet cell Abs and one of the precursors of the 40- and 37-kDa tryptic fragment islet autoantigens. To characterize autoantibody binding to IA-2 and determine whether humoral autoimmunity extends to other tyrosine phosphatases, we analyzed serum reactivity in 100 patients with insulin-dependent diabetes against different in vitro translated portions of the IA-2 protein as well as the tyrosine phosphatase domains of HPTPbeta and HPTPdelta. All autoantibody reactivity was confined to the cytoplasmic portion of IA-2 (amino acids 601-979). At least four epitopes were found. These were contained within amino acids 605 to 620 and 605 to 682 of the juxtamembrane region and within amino acids 777 to 937 and 687 to 979 in the IA-2 tyrosine phosphatase-like domain. Footprinting studies confirmed the presence of multiple epitopes. Fifty-six percent of sera with IA-2 Abs bound epitopes within the juxtamembrane region, and 83% bound epitopes in the tyrosine phosphatase-like domain; 39% had Abs to both regions. No reactivity against the IA-2 ectodomain or the tyrosine phosphatase domains of HPTPbeta and HPTPdelta was found. These data suggest that the cytoplasmic region, in particular the tyrosine phosphatase-like domain, is the major target of IA-2 Abs in insulin-dependent diabetes, and that autoantibody reactivity is specific for IA-2 or IA-2-like molecules.
Similar articles
-
IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens.J Immunol. 1998 Sep 1;161(5):2648-54. J Immunol. 1998. PMID: 9725268
-
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.J Immunol. 1998 Dec 15;161(12):6963-9. J Immunol. 1998. PMID: 9862731
-
Autoantigens in insulin-dependent diabetes mellitus: molecular cloning and characterization of human IA-2 beta.Proc Assoc Am Physicians. 1997 Jul;109(4):429-39. Proc Assoc Am Physicians. 1997. PMID: 9220540 Clinical Trial.
-
Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes.Diabetologia. 1999 Jan;42(1):3-14. doi: 10.1007/s001250051105. Diabetologia. 1999. PMID: 10027571 Review. No abstract available.
-
Immunomodulation with human recombinant autoantigens.Trends Immunol. 2005 Nov;26(11):608-12. doi: 10.1016/j.it.2005.08.015. Epub 2005 Sep 8. Trends Immunol. 2005. PMID: 16153889 Review.
Cited by
-
Affinity purification of serum-derived anti-IA-2 autoantibodies in type 1 diabetes using a novel MBP-IA-2 fusion protein.Biochem Biophys Rep. 2022 Dec 16;33:101413. doi: 10.1016/j.bbrep.2022.101413. eCollection 2023 Mar. Biochem Biophys Rep. 2022. PMID: 36578528 Free PMC article.
-
Immunoreactivities Against Different Tyrosine-Phosphatase 2 (IA-2)(256-760) Protein Domains Characterize Distinct Phenotypes in Subjects With LADA.Front Endocrinol (Lausanne). 2022 Jun 24;13:921886. doi: 10.3389/fendo.2022.921886. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35813648 Free PMC article.
-
Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Curr Diab Rep. 2017 Aug 8;17(10):84. doi: 10.1007/s11892-017-0914-z. Curr Diab Rep. 2017. PMID: 28791576 Free PMC article. Review.
-
Islet Autoantibodies.Curr Diab Rep. 2016 Jun;16(6):53. doi: 10.1007/s11892-016-0738-2. Curr Diab Rep. 2016. PMID: 27112957 Review.
-
The case for an autoimmune aetiology of type 1 diabetes.Clin Exp Immunol. 2016 Jan;183(1):8-15. doi: 10.1111/cei.12699. Epub 2015 Oct 21. Clin Exp Immunol. 2016. PMID: 26313217 Free PMC article. Review.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Other Literature Sources
Medical